We selected lansoprazole due to some anti-tumoral advantages such as suppression of tumor necrosis factor α (TNFα), NF-kB activity, phosphorylation of ERK [239], decreased adhesion of cancer cells to the matrix [240], synergy with metronomic chemotherapy [241], and synergy with carbonic acid inhibitors [242]. Here, TNF is linked to cancer.